PHARMACY

DSN editor addresses complexities of prescription drug anti-abuse policy in popular DC blog

BY DSN STAFF

In an op-ed in The Hill — a leading publication for members of Congress, policy makers and other Washington influencers — Drug Store News editor Rob Eder argues for the enactment of the Ensuring Patient Access and Effective Drug Enforcement Act (S. 483/H.R. 471). The bill would bring together enforcement and health agencies, and important stakeholders — including community pharmacy — to generate new and effective solutions to help prevent prescription drug abuse while protecting access for legitimate patients. Click here to read the complete post

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Liletta from Actavis, Medicines360 now available in the U.S.

BY Ryan Chavis

DUBLIN and SAN FRANCISCO — Actavis and Medicines360, a nonprofit women’s health pharmaceutical company, on Monday announced that Liletta (levonorgestrel-releasing intrauterine system) in 52 mg is now available in the United States. Liletta is used by women to prevent pregnancy for up to three years, according to the companies.
 
Liletta was granted Food and Drug Administration approval in February. It’s placed in the uterus by a healthcare professional and provides a continuous release of levonorgestrel to prevent pregnancy, the companies stated. 
 
"The availability of Liletta marks another significant achievement in women's health," said Carolyn Westhoff, MD, M.Sc, professor, division director, Family Planning and Preventive Services, Columbia University Medical Center. "It's critical that women have choices when it comes to their preferred contraception and I am pleased that I can offer my appropriate patients this new safe and effective option."
 
Liletta is now commercially available in doctor’s offices. Through the Actavis-Medicine360 partnership, it’s priced lower for public health clinics enrolled in the 340B Drug Pricing Program. 
 
"The commercial availability of Liletta represents a remarkable next step for women's health in the U.S., providing IUD-appropriate women, regardless of income and insurance coverage, with a safe and effective contraceptive option," said Pamela Weir, COO of Medicines360. "Through this truly innovative partnership, women will now have an accessible, affordable option for effective, long-term contraception."

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Sunny Pharmtech, Vitruvias Therapeutics to co-develop portfolio of generics

BY Ryan Chavis

MONTGOMERY, Ala. and TAIPEI, Taiwan — Taiwan-based drug development company Sunny Pharmtech and Vitruvias Therapeutics, a generic drug development company, on Tuesday announced that they will team up to co-develop a portfolio of generic drug products.
 
According to the companies, the partnership will allow them to “develop and commercialize generic products in markets that currently exceed $400 million.” Each company will have a 50% stake in the portfolio of products and the first abbreviated new drug application is expected to be filed in fourth-quarter 2015. 
 
“We are fortunate to have the opportunity to partner with a company as technologically sophisticated as Sunny Pharmtech given their expertise in the development of API and finished dose formulations,” said Carl Whatley, general manager of Vitruvias. “Sunny Pharmtech provides us with the know-how to develop difficult products in under-served U.S. markets and we look forward to addressing the needs of those markets as soon as we possibly can.”
 
Dr. Yon-Lian Wu, Sunny Pharmaceutical CEO and chairperson, added: “I am delighted to announce this strategic partnership between Sunny Pharmtech and Vitruvias. It will leverage both companies’ respective strengths to meet the needs of patients for high quality and cost-effective generic pharmaceuticals. For Sunny Pharmtech, this agreement will enhance our efforts to establish a world-class platform to support our efforts in the generic pharmaceutical products area. By combining our respective capabilities in this joint effort, Sunny Pharmtech and Vitruvias are creating a global business model and a robust base in the generic pharmaceuticals market.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?